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Epileptic encephalopathies are an epileptic condition characterized by epileptiform abnormalities associated with progressive
cerebral dysfunction. In the classiﬁcation of the International League Against Epilepsy eight age-related epileptic encephalopathy
syndromes are recognized. These syndromes include early myoclonic encephalopathy and Ohtahara syndrome in the neonatal
period, West syndrome and Dravet syndrome in infancy, myoclonic status in nonprogressive encephalopathies, and Lennox-
Gastaut syndrome, Landau-Kleﬀner syndrome, and epilepsy with continuous spike waves during slow wave sleep in childhood
and adolescences. Other epileptic syndromes such as migrating partial seizures in infancy and severe epilepsy with multiple
independent spike foci may be reasonably added. In this paper, we provide an overview of epileptic encephalopathies including
clinicalneurophysiologicalfeatures,cognitivedeterioration,andmanagementoptionsespeciallythattheseconditionsaregenerally
refractory to standard antiepileptic drugs.
1.Introduction
Epileptic encephalopathy is deﬁned as a condition in
which epileptiform abnormalities are believed to contribute
to the progressive disturbance in cerebral function, but
this deﬁnition may be ambiguous [1]. The report of the
International League Against Epilepsy (ILAE) Task Force on
classiﬁcation and terminology includes 8 syndromes under
epileptic encephalopathies: early myoclonic encephalopathy,
Ohtahara syndrome, West syndrome, Dravet syndrome,
myoclonic status in nonprogressive encephalopathies,
Lennox-Gastaut syndrome, Landau-Kleﬀner syndrome, and
epilepsy with continuous spike waves during slow-wave sleep
[1]. To these syndromes, the migrating partial seizures in
infancy and severe epilepsy with multiple independent spike
foci may be reasonably added [2].
A common feature is that these disorders are usu-
ally refractory to standard antiepileptic drugs (AEDs) [3].
As a result, more aggressive use of AEDs considered
eﬀective in suppressing interictal epileptiform discharges
(e.g., benzodiazepines, valproic acid, and lamotrigine),
immunomodulatory therapies (e.g., corticosteroids, intra-
venous immunoglobulin (IVIG), and plasmapheresis), keto-
genic diet, and surgical options is often considered [3]. In
this paper, epileptic encephalopathies will be dealt with in
the following concept: a particular group of usually age-
related and extremely intractable epilepsies with charac-
teristic generalized minor seizures and massive epileptic
EEG abnormalities, both of which cause stagnation or
deterioration in mental and cognitive functions in addition
to the preexisting developmental deﬁcit due to organic brain
damage [1–3].
2. Epileptic Encephalopathy
Syndromes inInfancy
2.1. Early Infantile Epileptic Encephalopathy (Ohtahara Syn-
drome). Ohtahara syndrome is the earliest form of the age-
dependent neonatal epileptic encephalopathies and was ﬁrst
described by Ohtahara and colleagues in 1976 [4]. It is often
deﬁned as “Early Infantile Epileptic Encephalopathy (EIEE)
with burst-suppression” or “early myoclonic encephalopathy
(EME)” [4]. Symptoms appear within the ﬁrst 3 months of
birth and usually within the ﬁrst 10 days. Often symptoms
will appear with the ﬁrst few hours after birth, and in
some cases mothers have felt possible seizures activity in
utero. Onset is acute in previously normal children [4].2 Epilepsy Research and Treatment
Main seizure pattern is tonic spasms; other patterns include
tonic/clonic, clonic, myoclonic, atonic, absences, partial,
complex partial (with or without secondary generalization),
gelastics, and Jacksonians. Seizures can appear in clusters
or singly and patterns are likely to change with time.
It is not uncommon for patterns to reappear at a later
stage [4]. EEG pattern is characterized as burst suppression
during both waking and sleeping states. This means that
the EEG (electroencephalogram) tends to show periods of
very little electrical brain activity followed by a burst of high
spiky activity before returning to very low activity again.
Sometimes, one side of the brain seems to be aﬀected more
than the other [5]. Seizures are intractable; although in some
cases they can be improved through treatment. In general
prognosis is poor with severe psychomotor retardation
and signiﬁcant learning diﬃculties. Frequently cases will
progress to West syndrome or partial epilepsy (usually
during infancy). Later a much smaller number develops to
Lennox-Gastaut syndrome. Psychomotor development may
be slightly better if the infants do not develop West or
Lennox-Gastaut syndrome. Half of the children are likely to
die in infancy or childhood [5, 6]. Although the disorder in
incurable, much can be done to improve the lives not only
of the children but also of the families. Seizure control is the
main aim and will be attempted either through optimized
dosages of anticonvulsants such as vigabatrin (Topamax),
Dilantin, Zonegran, and Phenobarbitone, or through steroid
therapies using ACTH and Prednisone. AEDs can be taken
in either mono- or polytherapies. The quest for seizure
control can be a slow and frustrating process. There is also
the possibility of utilizing such treatments as the ketogenic
diet, the VNS, or more invasive surgery, such as a partial
resection or complete hemispherectomy. Physiotherapy and
occupational therapies can help improve motor skills, while
hippotherapy can help improve general mobility, strength,
and endurance [7].
2.2. Early Myoclonic Encephalopathy. Early myoclonic en-
cephalopathy, an epileptic syndrome with onset either in
the neonatal period or the ﬁrst months of life, is character-
ized by erratic, fragmentary, or massive myoclonus, partial
seizures, and late tonic spasms. The prognosis is severe.
Early myoclonic encephalopathy is characterized clinically
by the onset of erratic or fragmentary myoclonus. Other
types of seizures, including simple partial seizures, massive
myoclonia, and tonic spasms, can also occur. Erratic, partial
myoclonus usually appears as the ﬁrst seizure, even as early
as a few hours after birth. The myoclonus usually involves
the face or extremities and may be restricted to an eyebrow,
a single limb, or a ﬁnger. The jerks occur when infants are
awake or asleep, and they are often described as “erratic”
because they shift typically from one part of the body to
another in a random, asynchronous fashion.
Frequency varies from occasional to almost continu-
ous. In addition to limited partial myoclonus, generalized
myoclonus may also be observed occasionally in some cases.
Partial seizures are frequent and occur shortly after erratic
myoclonus. The semiology of partial seizures is subtle,
consisting, for instance, of eye deviation or autonomic
phenomena such as apnea or ﬂushing of the face. Tonic
seizures are reported frequently and can occur in the ﬁrst
month of life or afterwards; they may occur both in sleep
and wakefulness. From a clinical standpoint, the child
presents a diﬀuse tonic contraction, usually extending to
the extremities. Real epileptic spasms are rare and generally
appear later. Neurologic abnormalities are constant: very
severedelayinpsychomotoracquisitions,markedhypotonia,
and disturbed alertness, sometimes with vegetative state.
Signs of peripheral neuropathy may also occur in rare
cases [8]. Early myoclonic encephalopathy is believed to
have various prenatal etiologies that often remain unknown.
Some conditions, such as inborn error of metabolism,
can produce the clinical and EEG picture typical of early
myoclonic encephalopathy such as nonketotic hyperglycin-
emia, D glyceric acidemia, propionic acidemia, molybde-
num cofactor deﬁciency, and methylmalonic acidemia. Few
patients present with a clinical picture similar to early
myoclonic encephalopathy with atypical burst-suppression
pattern that recover completely after pyridoxine therapy.
Some malformative disorders can also cause early myoclonic
encephalopathy, but more often they produce Ohtahara
syndrome [9]. In early myoclonic encephalopathy, EEG is
characterized by a “burst-suppression” pattern with bursts
of spikes, sharp waves, and slow waves, which are irregularly
intermingled and separated by periods of electrical silence
(Figure 1). The EEG paroxysms may be either synchronous
or asynchronous over both hemispheres. There is no normal
background activity. The burst-suppression pattern usually
evolves into atypical hypsarrhythmia or into multifocal
paroxysms after 3 to 5 months of life. Erratic myoclonus
does not generally have an ictal EEG counterpart. Partial
seizures have EEG characteristics similar to those of neonatal
ﬁts. The CT and MR ﬁndings vary and are related to
etiology. The brain may be either grossly normal or have
asymmetrical enlargement of one hemisphere, dilatation
of the corresponding lateral ventricle, or cortical and
periventricular atrophy [10]. Considering the inborn error
of metabolism reported above, the serum levels of amino
acids should be determined, especially glycine and glycerol
metabolites and organic acids, as well as the amino acids
in the cerebrospinal ﬂuid [4, 8, 9]. The prognosis for early
myoclonic encephalopathy is poor and there is no eﬀective
therapy for early myoclonic encephalopathy [9, 10].
2.3. Infantile Spasms (West Syndrome). West syndrome usu-
ally occurs in the ﬁrst year of life and consists of the triad
of infantile spasms, developmental deterioration, and a hyp-
sarrhythmia pattern on EEG [11]. The epileptic spasms are
brief, generalized seizures involving extension and/or ﬂexion
axially, and of the extremities. An individual spasm lasts
for seconds, often longer than typical myoclonic seizures,
though not as long as most tonic seizures. The spasms may
be subtle and may be isolated at onset, typically clustering
later in the course. Several clusters per day, particularly in
drowsiness, are characteristic [11, 12]. Hypsarrhythmia, the
typical interictal EEG ﬁnding, consists of a disorganizedEpilepsy Research and Treatment 3
 
Figure 1: EEG is characterized by a “burst-suppression” pattern
with bursts of spikes, sharp waves, and slow waves (arrow), which
are irregularly intermingled and separated by periods of electrical
silence (arrow head).
pattern with asynchronous, very high amplitude slowing
and frequent multifocal spike and sharp wave discharges
(Figure 2). The ictal EEG typically reveals a generalized
slow wave followed by a diﬀuse voltage attenuation (electro-
decrement) (Figure 3), which may associate with a spasm
or be only electrographic (without clinical correlation)
[12]. No clear etiology is found in approximately 40% of
cases. There is a broad range of potential causes, including
cerebral malformations, infection, hemorrhage, hypoxic-
ischemic injury, metabolic disorders, and genetic conditions,
such as Down syndrome [12, 13]. Variation in studying
methodologies prohibits a clear recommendation for ﬁrst
line treatment; however, ACTH and vigabatrin are usually
used in practice. Corticosteroids may be less eﬃcacious
than ACTH, although they are eﬀective. Vigabatrin may
be more eﬃcacious in tuberous sclerosis. Other agents that
are eﬃcacious include valproate, levetiracetam, topiramate,
zonisamide, lamotrigine, and benzodiazepines [11]. The
ketogenic diet is helpful in most cases [12]. Focal corti-
cal resection or hemispherectomy may be considered for
cases that are lesional and medically intractable [11–13].
Development remains unaﬀected only in a minority. Most
children experience slowing, plateauing, or regression of
theirdevelopmentaltrajectory.Thedevelopmentalprognosis
partially depends on the etiology. No speciﬁc AED has
been shown to aﬀect long-term developmental outcome. An
extensive literature review revealed that 16% had normal
development, and 47% had continued seizures at an average
followup of 31 months. When classiﬁed by etiology, normal
development was described in 51% of cryptogenic cases
versus only 6% of symptomatic cases. Approximately 17% of
cases evolved into Lennox-Gastaut syndrome [12].
2.4. Malignant Epilepsy with Migrating Partial Seizures in
Infancy. Onset of this rare syndrome occurs in the ﬁrst
year of life and may occur in the neonatal period. It is
characterizedby frequentpartial seizuresof multifocal onset,
with autonomic or motor involvement. The seizures increase
in frequency and may become near continuous. Clinical
Figure 2: Hypsarrhythmia, the typical interictal EEG ﬁnding,
consists of a disorganized pattern with asynchronous, very high
amplitude slowing and frequent multifocal spike and sharp wave
discharges (arrows).
Figure 3: The ictal EEG in West syndrome typically reveals a
generalized slow wave followed by diﬀuse voltage attenuation
(electrodecrement), which may associate with a spasm or be only
electrographic without clinical correlate (arrows).
semiology of the seizures include lateral head and eyes
deviation, focal clonic seizures of the eyes, face or limbs,
unilateral or bilateral focal tonic seizures, automatic move-
ments such as chewing, mastication, autonomic features
such as apnea, salivation or facial ﬂushing and secondary
generalized tonic clonic seizures. The interictal EEG reveals
multifocal epileptiform activity and slowing, diﬀuse slowing
of the background activity. A few patients may have a normal
EEG. Then the EEG background activity became slow with
ﬂuctuatingasymmetry betweendiﬀerentrecordings. Initially
sleep-waking cycle can be identiﬁed; spindles are rare and
asymmetric.TheictalEEGconﬁrmsmultifocalonsets,which
may shift from seizure to seizure. In most cases, there is
no clear etiology or structural problems, suggesting that
genetic factors may be causative or contributory. Seizures
are often diﬃcult to control with standard AEDs. Bromides,
stiripentol, and clonazepam may be helpful in some cases.
Developmental regression is common, and death has been
reported in infancy and childhood in severe cases [14].
2.5. Myoclonic Status in Nonprogressive Encephalopathies.
This rarely reported disorder has onset in infancy or early
childhood, with onset usually during the ﬁrst year of life.
Seizurestypicallybeginwithpartialmotorseizures,although4 Epilepsy Research and Treatment
myoclonic status may occur at onset. Myoclonic absences,
massive myoclonias, and rarely generalized or hemiclonic
seizures may occur. Myoclonias may be multifocal and occur
with startles. Myoclonic status epilepticus may be recurrent.
Motor abnormalities and movement disorders are common.
The interictal EEG consists of multifocal epileptiform dis-
charges and background slowing. Epileptiform discharges
are potentiated in sleep, in some cases similar to an ESES
pattern. Ictal EEG recording may demonstrate generalized
slowspikeandwave,oranabsencepattern,dependingonthe
seizure type. A genetic cause is identiﬁable in approximately
half of children, including Angelman syndrome and 4p-
syndrome. Other reported causes include hypoxic-ischemic
injury and cortical dysplasia. Episodes of myoclonic status
may respond to benzodiazepines. AEDs that may be eﬃ-
cacious include valproate with ethosuximide or clobazam.
Children have a poor prognosis, experiencing developmental
regression and eventual severe mental retardation. The
repeated episodes of myoclonic status may contribute to
cognitive deterioration [15].
2.6. Severe Myoclonic Epilepsy in Infancy (SMEI) Dravet Syn-
drome. This is an uncommon form of childhood epilepsy.
Out of 500 children with epilepsy, only one, or at most two,
child is likely to have this form of epilepsy. It is also called
Dravet syndrome. The epilepsy starts with seizures which
may not initially diﬀer from those associated with feverish
illnesses. This syndrome tends to develop during the second
yearoflife.Itmaynotbepossibletomakethisdiagnosisuntil
the child is two, three, or even four years old. The seizures
begin in the ﬁrst year of life. They are most often associated
with high temperatures and often just involve one side of the
body, although both sides of the body may be involved. The
seizures are characterized by jerking rather than stiﬀness and
jerking. They often recur quite frequently in the ﬁrst year of
life. However, at this time it is not easy to diﬀerentiate these
children from others with febrile convulsions who get better
and who do not go on to develop other types of seizure.
During the second year of the life of children with SMEI,
seizures become more frequent and persistent, are often
more obviously partial (involving one part of the body), and
no longer occur when a child has a high temperature but at
any time of day and night. In addition to the partial seizures
arethemyoclonicjerks.Oftenthechildrenarephotosensitive
(have seizures brought on by ﬂashing lights). Seizures may
also sometimes be brought on by hot environments or
hot showers or baths. The early development of aﬀected
children is usually normal but once the myoclonic seizures
and partial seizures start in their second year of life, children
may lose skills or their developmental progress may slow
down. The child’s speech and language may be particularly
aﬀected.Theelectroencephalogram(EEG)whichrecordsthe
electrical activity in the brain is usually normal early in this
condition. Later, by the time the child is 18 months old,
there is evidence of epileptic activity with spike and wave
or polyspike discharges, which occur either as single event
or in bursts. These may be generalized involving the whole
brain or occurring just from on small area of the brain.
Some children show EEG evidence of sensitivity to ﬂashing
lights but this does not occur in all. Brain scans are usually
normal. More recently a speciﬁc genetic abnormality, called
a “mutation”, has been found in at least 70 per cent of
children with SMEI. This mutation is known as the “SCN1A”
mutation. It is likely that other mutations will also be found
in children with SMEI. The mutation can be looked for
in a simple blood test and this has been very helpful in
making or conﬁrming a diagnosis of this epilepsy syndrome.
SMEI is very resistant to anti-epileptic drugs. Phenobarbital,
sodium valproate (Epilim), and lamotrigine (Lamictal) are
usually tried ﬁrst. However, lamotrigine may actually make
the myoclonic seizures worse in many children. Other
options include a medication called stiripentol, topiramate
(Topamax), clonazepam (Rivotril), and clobazam (Frisium).
A combination of sodium valproate with either topiramate
or stiripentol may be the most helpful. A short course of a
steroid (called prednisolone) and the ketogenic diet may also
be helpful. Because children with SMEI always have learning
diﬃculties, they will also need full educational assessment
and support [16, 17].
3. Epileptic Encephalopathy
Syndromes inChildhood
3.1. Lennox-Gastaut Syndrome LGS. Childhood epileptic
encephalopathy, or Lennox-Gastaut syndrome (LGS), is a
devastating pediatric epilepsy syndrome constituting 1–4%
of childhood epilepsies. The syndrome is characterized by
multiple seizure types; mental retardation or regression;
abnormal ﬁndings on electroencephalogram (EEG), with
paroxysms of fast activity and generalized slow spike and
wave discharges (1.5–2Hz) (Figure 4). The most common
seizure types are tonic-axial, atonic, and absence seizures,
but myoclonic, generalized tonic-clonic, and partial seizures
can be observed (see clinical presentation). An EEG is an
essential part of the workup for LGS. Neuroimaging is an
important part of the search for an underlying etiology. LGS
can be classiﬁed according to its suspected etiology as either
idiopathic or symptomatic. Patients may be considered to
have idiopathic LGS if normal psychomotor development
occurred prior to the onset of symptoms, no underlying
disorders or deﬁnite presumptive causes are present, and
no neurologic or neuroradiologic abnormalities are found.
In contrast, symptomatic LGS is diagnosed if a likely cause
can be identiﬁed as being responsible for the syndrome.
Population-basedstudieshavefoundthat70–78%ofpatients
with LGS have symptomatic LGS. Underlying pathologies in
these cases include encephalitis and/or meningitis, tuberous
sclerosis, brain malformations (e.g., cortical dysplasias),
birth injury, hypoxia-ischemia injury, frontal lobe lesions
and trauma. Overall, LGS accounts for 1–4% of patients
with childhood epilepsy but 10% of patients with onset
of epilepsy when younger than 5 years. The prevalence of
LGS in Atlanta, GA, USA, was reported as 0.26 per 1000
live births. LGS is more common in boys than in girls.
The prevalence is 0.1 per 1000 population for boys, versus
0.02 per 1000 population for girls (relative risk, 5.31). TheEpilepsy Research and Treatment 5
 
Figure 4: EEG in Lennox-Gastaut syndrome with paroxysms of fast
activity and generalized slow spike and wave discharges (1.5–2Hz)
(arrows).
mean age at epilepsy onset is 26–28 months (range, 1d to
14y). The peak age at epilepsy onset is older in patients
with LGS of an identiﬁable etiology than in those whose
LGS has no identiﬁable etiology. The diﬀerence in age
of onset between the group of patients with LGS and a
history of West syndrome (infantile spasm) and those with
LGS without West syndrome is not signiﬁcant. The average
age at diagnosis of LGS in Japan was 6 years (range, 2–
15y). Epidemiologic studies in industrialized countries (e.g.,
Spain, Estonia, Italy, and Finland) have demonstrated that
theproportionofepilepticpatientswithLGSseemsrelatively
consistent across the populations studied and similar to that
in the United States. The prevalence of LGS is 0.1–0.28 per
1000 population in Europe. The annual incidence of LGS in
childhood is approximately 2 per 100,000 children. Among
children with intellectual disability, 7% have LGS, while
16.3%of institutionalized patients withintellectualdisability
have LGS. Long-term prognosis overall is unfavorable but
variable in LGS. Longitudinal studies have found that a
minority of patients with LGS eventually could work nor-
mally, but 47–76% still had typical characteristics (mental
retardation, treatment-resistant seizures) many years after
onset and required signiﬁcant help (e.g., home care, insti-
tutionalization). A variety of therapeutic approaches are
used in LGS, ranging from conventional antiepileptic agents
to diet and surgery. Unfortunately, much of the evidence
supporting these approaches is not robust, and treatment
is often ineﬀective. The medical treatment options for
patients with LGS can be divided into the following 3 major
groups: The medical treatment options for patients with LGS
include the use of antiepileptic drugs such as valproic acid
and benzodiazepines such as clonazepam, nitrazepam and
clobazam, vigabatrin, zonisamide, lamotrigine, topiramate
and ruﬁnamide proven eﬀective by double-blind placebo-
controlled studies (e.g., lamotrigine, topiramate, felbamate,
andruﬁnamide).Theketogenicdietmaybeusefulinpatients
with LGS refractory to medical treatment. Surgical options
forLGSincludecorpuscallosotomy,vagusnervestimulation,
and focal cortical resection [18–21].
3.2. Electrical Status Epilepticus during Slow Sleep (ESES).
A disorder in which sleep induced an EEG pattern charac-
terized by “subclinical” spikes and waves occurring almost
continuously during slow sleep and appearing every night
for a variable length of time in children was reported
under the title of “subclinical electrical status epilepticus
induced by sleep in children”. The disorder was later termed
“electrical status epilepticus during sleep” [22]. The clinical
manifestations of this syndrome include a status heteroge-
neousepilepticdisorder,deteriorationofneuropsychological
functions associated with or independent from the epileptic
disorder, and deterioration of motor functions. The typical
EEG pattern of continuous spikes and waves during slow
sleep (Figures 5 and 6) is also an essential and absolute
featurefortherecognitionofthesyndrome.Theageatwhich
the ﬁrst seizure occurs ranges between 2 months and 12
years, with a peak around 4 and 5 years. This event can
be preceded by either normal psychomotor development
or abnormal signs indicating preexisting encephalopathy
such as hemiparesis, hemiplegia, spastic quadriplegia, diﬀuse
hypotonia, and ataxia. The seizure types occurring in the
disorder can be both partial and generalized. They include
unilateral or bilateral clonic seizures, generalized tonic-
clonic seizure, absences, partial motor seizures, complex
partial seizures, or epileptic falls. They may occur during
wakefulness or sleep. Tonic seizures, however, never occur.
The ﬁrst seizures are reported to be nocturnal and of
unilateral type in almost one-half of the cases reported. At
onset, the frequency of seizure attacks is low. At the time
of discovery of the typical nocturnal EEG pattern, however,
the epileptic seizures frequently change in severity and
frequency. Absences and epileptic falls herald the appearance
of continuous spikes and waves during slow sleep and
seizure frequency increases, both during wakefulness and
sleep. About 60% of patients also exhibit several types of
seizures [22, 23]. The characteristic feature of this disorder
is the appearance of continuous spike-wave discharges on
the EEG during slow sleep. Most researchers assert that
more than 85% of NREM sleep is occupied by spike-wave
discharges; however, quantitative studies of diﬀerent sleep
stages and of temporal evolution of this EEG disturbance
have not been carried. The typical EEG changes appear 1
year to 2 years after the ﬁrst seizure and are associated with
behavioral deterioration. Focal and generalized interictal
spikes occur before this time and persist during wakefulness
and REM sleep after the appearance of continuous spike
waves during slow-wave sleep [24]. The cause of electrical
status epilepticus during slow sleep is unknown. Long-
lasting persistence of continuous spike waves during sleep
is postulated to be responsible for the neuropsychiatric
abnormalities in electrical status epilepticus during slow
sleep; secondary bilateral synchrony is the mechanism
underlying continuous spikes and waves during slow sleep.
In this respect the apparent generalized seizures (absences,
tonic-clonic attacks) occurring in this condition have in
fact a focal onset as demonstrated by interhemispheric peak
latencies of their EEG correlates, phase reversal of spikes
on unilateral frontal regions, and studies of coherence and
phase analyses. A localized metabolic abnormality has been
also revealed by means of PET studies. Therefore, although
electrical status epilepticus during slow sleep is currently
classiﬁed among the epilepsies undetermined whether focal6 Epilepsy Research and Treatment
or generalized, consistent data support the view that this
syndrome is to be included in the domain of localization-
related epilepsies, of cryptogenic or symptomatic nature
[23–25]. Electrical status epilepticus during slow sleep is a
rare order. One study revealed an incidence of 0.5% among
12,854 children evaluated during a 10-year period. There
is no obvious gender preponderance [23] .T h es e i z u r e si n
electrical status epilepticus during slow sleep are self-limited
and disappear in the midteens. The good seizure outcome is
independentoftheetiologyandisobservedalsoincaseswith
cortical malformations such as multilobar polymicrogyria.
The characteristic EEG patterns during slow-wave sleep also
disappearatapproximatelythesametime,butfocalinterictal
spikes may persist. Improvement in language dysfunction,
mental retardation, and psychiatric disturbances generally
occurs but it is variable and individualized. The majority of
aﬀected children never return to normal levels, particularly
in the verbal area and attention [25, 26]. Epileptic seizures
may or may not respond to a variety of drugs including ben-
zodiazepines, valproate, ethosuximide, carbamazepine, and
phenytoin.Despiteofthefactthattheseizuresmayberefrac-
tory to therapy for months to years, the long-term prognosis
of epilepsy is favorable with the disappearance of seizures
in all cases. Only benzodiazepines and adrenocorticotrophic
hormone have been reported to suppress the electrical
status and perhaps to improve language function. However,
the positive eﬀects are often transient [23]. In individual
cases, chronic oral treatment with clobazam, lorazepam, and
clonazepam associated with other antiepileptic drugs usually
valproate seemed to have a long-lasting eﬀect. Short cycles (3
to 4 weeks) of relatively high doses of diazepam (0.5mg/kg)
following a rectal diazepam bolus of 1mg/kg have also been
reported to be eﬀective. At the present time, the combined
use of benzodiazepines and valproate is considered the
treatment of choice in this condition. On the other hand,
polytherapy should be avoided. A detailed evaluation of
antiepileptic regimens in 88 patients demonstrated that the
reduction in polytherapy coincided with an improvement of
the syndrome. It was also suggested that the drug overload
and some medications (such as carbamazepine) could play
a role in the maintenance of continuous spikes and waves
duringslow sleep.Incasesofelectricalstatusepilepticus dur-
ing sleep with severe language impairment, a progressive and
long-lasting improvement of the language function has been
obtained applying the surgical procedure of multiple subpial
transections of the region of focal epileptic discharges [27].
3.3. Acquired Epileptic Aphasia Landau-Kleﬀner Syndrome
(LKS). Acquired epileptic aphasia typically develops in
healthy children who acutely or progressively lose receptive
and expressive language ability coincident with the appear-
ance of paroxysmal electroencephalographic (EEG) changes
[28].
In most cases described in detail, a clearly normal period
of motor and language development occurs before acquired
epileptic aphasia symptoms appear. However, in the last 2-3
decades, several reported cases have been diﬃcult to classify,
because the patients’ presenting symptoms appear to have
Figure 5: Electrical status epilepticus during slow sleep (ESES),
disappearance of spike waves with eye opening (arrows).
 
Figure 6: Electrical status epilepticus during slow sleep (ESES),
continuous spike-wave discharges on the EEG during slow sleep
(arrows).
variants of those originally described. In one case, expressive
language deteriorated instead of receptive language, whereas
in another case, a brief period of normal language devel-
opment (single words) was followed by language regression
with abnormal EEG ﬁndings. Acquired epileptic aphasia
must be diﬀerentiated from autism with minimal language
regression, especially when it is associated with isolated EEG
abnormalities. Many current researchers classify acquired
epileptic aphasia as part of the syndrome of electrical
status epilepticus of sleep (ESES) [25]. Whether seizures
and epileptiform discharges cause language dysfunction in
acquired epileptic aphasia (AEA) is disputed. Aphasia and
electroencephalographic (EEG) abnormalities might have a
common cause (e.g., a left temporal brain astrocytoma or
head injury). Some authors speculate that reinforcement of
synaptogenesis mediates the neurologic deﬁcits in acquired
epileptic aphasia and that epileptiform discharges during
a critical period of synaptic reinforcement or pruning in
turn mediate the reinforcement of synaptogenesis [28].
In aﬀected children, aphasia usually appears at age 4–7
years, and there is a slight male predominance (male-to-
female ratio, 1.7:1). However, symptom onset has been
described in patients as young as 18 months and in those
as old as 13 years. This discussion excludes the congenital
cases with typical electroencephalographic (EEG) patterns
and little or no language development; in such cases,Epilepsy Research and Treatment 7
the precise age of onset can never be determined. Long-
term outcome studies of patients with acquired epileptic
aphasia are limited by the lack of uniformity in diagnostic
criteria. About half the patients have some ﬂuctuation in
aphasia, and the ﬂuctuations usually occur over several
months. On occasion, aphasia may worsen for as long
as 7 years after the disease onset [29]. The treatment of
acquired epileptic aphasia is far from standard, and many
therapeutic modalities have been tried with variable success.
Among these are anticonvulsant drugs, corticosteroids (e.g.,
adrenocorticotropin hormone (ACTH)), ketogenic diet, and
surgical intervention with multiple subpial transections
(MSTs). The calcium channel blocker nicardipine has been
used in the treatment of acquired epileptic aphasia. In
the initial report of 4 patients that suggested the use
of nicardipine for acquired epileptic aphasia, nicardipine
was given in association with anticonvulsant medications
(carbamazepine, valproic acid) and corticosteroids (3 of 4
cases). However, cessation of nicardipine was associated with
acute speech deterioration. The dose of nicardipine was
1mg/kg/d or 60mg/d for large patients. A few case reports
have demonstrated that intravenous gamma globulin may
be useful in acquired epileptic aphasia, but repeated doses
may be necessary [30]. Many commonly used anticonvulsant
agents eﬀective against partial or generalized seizures have
been used in acquired epileptic aphasia with variable success.
Phenobarbital, carbamazepine, and phenytoin are often
ineﬀective in halting the electroencephalographic (EEG)
discharges, and aphasia may worsen the electrographic
activity. In a few cases, the drugs may actually worsen the
picture, especially in patients with drop seizures and atypical
absences. Valproic acid, ethosuximide, and benzodiazepines
alone or in combination have been partially or transiently
eﬀective in some cases. Benzodiazepines, especially clobazam
(in Europe) and midazolam, have been most eﬀective when
given intravenously (IV). Both the impracticality of this
mode of administration and its short-lived eﬀect have
limited its use. Diazepam 0.5mg/kg given rectally (PR) at
bedtime is sometimes eﬀective. This treatment is used in
4- to 6-week courses on and oﬀ to avoid tachyphylaxis.
The Boston Children’s Hospital Epilepsy Group has used
continuous diazepam 0.5–0.3mg/kg given orally (PO) in
acquired epileptic aphasia for periods up to 1 year. Several
studies have shown levetiracetam to be beneﬁcial when
used as monotherapy in the treatment of electrical status
epilepticus of sleep (ESES), continuous spike wave in slow-
wave sleep (CSWS), and benign idiopathic focal epilepsies in
childhood. In a recent study, Kramer et al. found clobazam
and levetiracetam to be the most eﬃcacious antiepileptic
drugs in the treatment of ESES. In a case report, felbamate
45mg/kg/d was successful in treating seizures and aphasia.
However, the high frequency of aplastic anemia and liver
dysfunction with this drug limits its use [31, 32].
4. Conclusions
Epileptic encephalopathies are severe brain disorders of early
age that manifest with (1) electrographic EEG paroxys-
mal activity that is often aggressive, (2) seizures that are
usually multiform and intractable, (3) cognitive, behav-
ioral and neurological deﬁcits that may be relentless,
and (4) sometimes early death. The concept of “epileptic
encephalopathies”isbasedontheassumptionthataggressive
ictal (seizure) and electrical (electrographic) epileptogenic
activity during brain maturation is the main causative factor
of progressive cognitive and neuropsychological deterio-
ration or regression. Conversely, this deleterious epileptic
activity is a speciﬁc age-related brain reaction of excessive
neocortical excitability to diﬀerent pathological conditions,
which are focal or diﬀuse, of symptomatic or idiopathic
cause. This age-related epileptogenic reaction is peculiar to
the immature brain and varies signiﬁcantly in accordance
with the stage of brain maturity at the time that this occurs.
Thus, EEG demonstrates primarily burst-suppression pat-
terns in the neonatal period, hypsarrhythmia in infancy,
and slow generalized spike-wave discharges (GSWDs) in
early childhood. With advancing age, the seizure and elec-
trographic epileptogenic features may evolve from one to
another age-related stage that is from burst suppression
to hypsarrhythmia and then to slow GSWD. All epileptic
encephalopathies have a tendency to abate, discontinue, or
even stop in adolescence but often with serious neurocogni-
tive residuals.
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